LabVantage and InforSense Ally to Redefine Enterprise Laboratory Informatics
News May 01, 2008
LabVantage Solutions, Inc and InforSense Ltd. have announced an alliance to integrate the InforSense platform with LabVantage’s flagship SAPPHIRE laboratory information management suite (LIMS) and for LabVantage to resell InforSense along with its SAPPHIRE LIMS.
"One of the key challenges that our customers face is how to integrate, analyze and visualize data from multiple data sources across their organization, including from SAPPHIRE, to support more efficient and effective decisions," stated Ronald Kasner, Vice President of Corporate Development for LabVantage. "SAPPHIRE’s operational workflow and data management capabilities coupled with INFORSENSE’s integration and analytics workflow capabilities offer customers a robust, yet flexible enterprise backbone for laboratory informatics – what we refer to as federated informatics," he added.
By leveraging configurable-off-the-shelf (COTS), modular driven products, rather than custom developed software or services, LabVantage can tailor point specific or enterprise wide solutions to address each organization’s unique needs. The combined SAPPHIRE and InforSense infrastructure leverages the modularity of both platforms to effectively aggregate, mine, and analyze data stored in SAPPHIRE and the SAPPHIRE modules coupled with data stored in other heterogeneous scientific and operational data sources, including in-house and proprietary R&D and manufacturing applications. Together, the platforms deliver a powerful and versatile laboratory informatics solution spanning discovery, development and manufacturing.
"LabVantage is a leading laboratory informatics player with pioneering vision and state-of-the-art technology and we are pleased to be working with them," said Dr. Jonathan Sheldon, CSO of InforSense. "InforSense’s capabilities to flexibly integrate and analyze data and deliver powerful interactive web based data visualization provides an incredible complement to LabVantage’s enterprise LIMS. The combined solution sets new standards for laboratory data integration and decision making."
"We’re excited to work with the leading enterprise workflow analytics company, and believe strongly in their people and technology," said Jim Aurelio, CEO & President of LabVantage. "With this alliance, LabVantage continues to redefine laboratory informatics and enable our customers to go beyond the world of traditional LIMS."
The SAPPHIRE BioBanking Solution will be the first to incorporate integrative analytics. Leveraging the BioBanking Module of SAPPHIRE, and the ClinicalSense Module of InforSense, LabVantage will couple the best of enterprise biorepository management with the best of translational research data integration and interactive analytics. LabVantage will feature ongoing demonstrations of its SAPPHIRE BioBanking Solution with Integrative Analytics at the Bio-IT World Congress and the Translational Research Symposiums in Boston late April and early May, respectively. To download a pre-recorded webcast of the solution, go to www.labvantage.com/webcasts/tm/pr/inforsense.html.
DDN Provides University of Tennessee’s SimCenter with Big Data Storage to Support Machine Learning and Data AnalyticsNews
DataDirect Networks (DDN®) today announced that The University of Tennessee, Chattanooga (UTC) has selected DDN’s GS14KX® parallel file system appliance with 1.1PB of storage to replace its aging big data storage system and to support a diversifying range of data-intensive research projects.READ MORE
Closer Look at Immune Proteins Provides Insight into Potential Pathogen Protection StrategiesNews
Biologists have resolved the structure of a ring of proteins used by the immune system to summon support when under attack, providing new insight into potential strategies for protection from pathogens.READ MORE
Computer Program Helps Find Ways to Repurpose Existing DrugsNews
Researchers have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, matches existing data about FDA-approved drugs to diseases, and predicts potential drug efficacy.READ MORE